Laura Martin, PA
Physician Assistant · Shelbyville, KYNPI 1558663534
Payments from drug & device makers
Across 262 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$762
- Lilly USA, LLC$543
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$496
- Vanda Pharmaceuticals Inc.$394
- Novo Nordisk$298
- Pfizer$247
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 64 | $762 |
| Lilly USA, LLC | 29 | $543 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $496 |
| Vanda Pharmaceuticals Inc. | 15 | $394 |
| Novo Nordisk | 19 | $298 |
| Pfizer | 14 | $247 |
| GSK | 15 | $243 |
| AstraZeneca | 9 | $232 |
| Amgen | 9 | $139 |
| Otsuka America Pharmaceutical, Inc. | 5 | $111 |
| Axsome Therapeutics, Inc. | 4 | $108 |
| Dynavax Technologies Corporation | 6 | $104 |
| Phathom Pharmaceuticals, Inc. | 5 | $101 |
| Johnson & Johnson | 4 | $81 |
| Verona Pharma, Inc. | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Astellas Pharma US Inc | 3 | $52 |
| Abbott | 3 | $47 |
| Alkermes, Inc. | 2 | $43 |
| Exact Sciences | 3 | $41 |
| Medtronic | 2 | $38 |
| Bayer | 2 | $38 |
| Novartis | 2 | $32 |
| BETA Bionics, Inc. | 1 | $31 |
| Lundbeck LLC | 1 | $27 |
| Almatica Pharma LLC | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Abiomed | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Axonics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,566 in reported general payments places this provider in the 90th percentile of 1,448 physician assistant providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $80,664 |
| JardianceEmpagliflozin | 59 | $44,199 |
| MounjaroTirzepatide | 42 | $42,940 |
| JanuviaSitagliptin Phosphate | 53 | $40,978 |
| EliquisApixaban | 57 | $36,317 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $22,764 |
| VraylarCariprazine Hcl | 11 | $14,689 |
| GemtesaVibegron | 18 | $13,160 |
| FarxigaDapagliflozin Propanediol | 12 | $9,882 |
| ProtonixPantoprazole Sodium | 11 | $9,711 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,389 |
| Repatha SureclickEvolocumab | 14 | $7,751 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $4,416 |
| VascepaIcosapent Ethyl | 12 | $4,285 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 36 | $3,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $298 | $80,66466 claims |
| PfizerEliquis, Protonix | $247 | $46,02968 claims |
| Boehringer IngelheimJardiance | $15 | $44,19959 claims |
| Lilly USA, LLCMounjaro | $543 | $42,94042 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $243 | $32,15357 claims |
| AbbVieVraylar | $762 | $14,68911 claims |
| AstraZenecaFarxiga | $232 | $9,88212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,448 physician assistant providers in Kentucky.
Other physician assistant in Shelbyville
- Brandice HarrisonLexington$745K
- Lauren MeadeLexington$656K
- Melissa DavisLouisville$362K
- Kara MuddLouisville$98K
- Seth KingBowling Green$91K
- Marty MullinsHazard$63K
- Lauri GarnerVersailles$33K
- Robert TatumLouisville$29K
- Michelle JonesLexington$29K
- Grace IsaacsLouisville$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.